Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Cyclic peptides
Reexamination Certificate
2011-05-10
2011-05-10
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Cyclic peptides
C514S011400, C530S311000
Reexamination Certificate
active
07939625
ABSTRACT:
The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
REFERENCES:
patent: 3863008 (1975-01-01), Grant
patent: 4292972 (1981-10-01), Pawelchak et al.
patent: 4505897 (1985-03-01), Coy et al.
patent: 4612366 (1986-09-01), Nutt
patent: 029310 (1981-05-01), None
patent: 389180 (1990-09-01), None
patent: 395417 (1990-10-01), None
patent: WO 90/12811 (1990-11-01), None
patent: WO 94/00489 (1994-01-01), None
patent: WO 95/00553 (1995-01-01), None
patent: WO 95/03330 (1995-02-01), None
patent: WO 95/04752 (1995-02-01), None
patent: WO 97/01579 (1997-01-01), None
patent: WO 97/05167 (1997-02-01), None
patent: WO 97/43278 (1997-11-01), None
patent: WO 98/04583 (1998-02-01), None
patent: WO 99/65508 (1999-12-01), None
patent: WO 00/12111 (2000-03-01), None
Tu W. (Journal of Immunology 165(3), 1331-1336, 2000).
ten Bokum (European Cytokine Network 11(2), 161-176, 2000).
Nguyen (AIDS 12(8) 895-904, 1998).
Borie, R., Thorax 63, 251-258, 2008.
Abstract of ten Bokum, Eur. Cytokine Network, 11(2), 161-176, 2000.
Huang et al., “Main Chain and Side Chain Chiral Methylated Somatostatin Analogs; Syntheses and Conformational Analyses”,J. Am. Chem. Soc., vol. 114, No. 24, pp. 9390-9401 (1992).
Rohrer et al., “Rapid Identification of Subtype-Selective Agonists of the Somastostatin Receptor Trhough Combinatorial Chemistry”,Science, vol. 282, pp. 737-740 (1998).
Pollak, Polychronakos and Guyda, “Somastostatin Analogue SMS 201-995 Reduces Serum IGF-I Levels in Patients with Neoplasms Potentially Dependent on IGF-I”,Anticancer Res., vol. 9, No. 4, pp. 889-892 (1989).
Lloyd-Williams et al., “Convergent Solid-Phase Peptide Synthesis,” Tetrahedron, vol. 49, No. 48, pp. 11065-11133 (1993).
Ballare Emillia et al: “Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment”, The Journal of Clinical Endocrinology & Metabolism 86(8), pp. 3809-3814 (2001).
ten Bokum AM et al: “Somatostatin and somatostatin receptors in the immune system: a review”, European Cytokine Network Jun. 2000; 11(2):161-76 (abstract).
Rao Goutham: “Insulin resistance syndrome”, American Family Physician vol. 63, No. 6, pp. 1159-1163 Mar. 15, 2001.
Yang Lihu et al: “Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 10836-10841 Sep. 1998.
Schmid: “Pasireotide (SOM230) as a potential treatment for endocrine and non-endocrine tumors”, Current Drug Therapy, 2010, vol. 5, pp. 301-311.
Schmid: “Pasireotide (SOM230): development, mechanism of action and potential applications”, Molecular and Cellular Endocrinology, vol. 286 (2008) pp. 69-74.
Albert Rainer
Bauer Wilfried
Bodmer David
Bruns Christian
Felner Ivo
Houghton Gregory C.
Lukton David
Novartis AG
LandOfFree
Somatostatin analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Somatostatin analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Somatostatin analogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2690030